Takis

Meet Denise Svegliati, our talented Administrative Support Specialist! At 26, Denise is a university student pursuing a degree in Languages and Literature for Intercultural Communication. She joined Takis in May 2023 and has quickly become an integral part of our team. Denise wears many hats at Takis, excelling as our Administrative Support Specialist, Warehouse Manager, and Travel Organizer. Her sights are set on advancing into the role of Management Secretary, a goal she’s already working toward by skillfully managing schedules for our leadership team and coordinating company events. We deeply value Denise’s dedication and enthusiasm and look forward to supporting her continued growth with us!

Save the Date: November 27th-28th in Lyon! Join us at the 8th Immunotherapies & Innovations for Infectious Diseases Congress (I4ID Congress), where Takis will be present as an exhibitor and as speaker! We will have the booth number 7, where you will find our own laura luberto, Antonella Conforti, Alessia Muzi and Giuseppe Roscilli, ready to welcome you and share our latest research. We're also thrilled to announce that Antonella Conforti from Takis will deliver a talk on “Development of novel genetic vaccine platforms for epidemic preparedness: from the idea to GMP production,” sharing our advancements in vaccine development. This two-day congress brings together pharmaceutical industries, research labs, technology developers, and clinicians to foster #collaboration and #innovation in the fight against infectious #diseases. In addition to the scientific program, the event offers networking opportunities, a showcase for new technologies, and a dedicated online B2B platform for business partnering. Looking forward to connecting with industry peers and advancing the future of infectious disease #immunotherapy. See you in Lyon!

During the 31st Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), our talented Eleonora Pinto from the #Immunology team presented a #poster titled "Development of Novel Genetic Vaccine Platforms: From the Idea to GMP Production”. The #ESGCT #Congress centered on advancing #genetherapy, #celltherapy, and #geneticvaccines by fostering #research and facilitating the exchange of knowledge and technology throughout Europe. We are happy to have contributed to the event with this research work. Check it out in this carousel!

From November 5th to 7th, we had the privilege of joining and chairing a session at the 16th Annual #PEGS Europe Summit. Held at Montjuic Palau de Congressos in Fira #Barcelona, the event is celebrated as 'the best #biologics technology meeting in Europe,' attracting over 1,500 experts and innovators from across the globe. Giuseppe Roscilli, our Chief Technology Officer, presented our latest advancements in #antibody engineering and innovative therapeutic strategies, with a focus on our groundbreaking work with bispecific antibodies targeting HER3. It was an honor to lead discussions in the “Next-Generation Immunotherapies” session, which explored a range of innovative strategies including anti-TNFR2 strategies, IL-18 receptor antibody agonists, neoantigen vaccine optimization, and antibody-cytokine fusion proteins. The conference featured extensive programs, such as Antibody and Protein Engineering, Oncology, Machine Learning & Data Science and Immunotherapy, highlighting the newest advancements and technologies of antibody-based treatments. It was an incredible experience to network, exchange knowledge, and collaborate with leaders in the field. Thanks to PEGS Europe for an inspiring and impactful event!

From every crisis there is an opportunity… this is our story in a nutshell - wonderfully reported by #RaiNews in this segment! Our company was born from the hashes of layoffs from multinational companies. But it turned out to be the spark for an exciting journey. After 15 years, we are proud to have inaugurated an innovative BSL-3 lab as well as produced impactful research on genetic vaccines and immunotherapies. Our COO, Emanuele Marra, provided insights into the new BSL-3 facility, explaining how it enables researchers to “study highly dangerous pathogens and develop the best therapies.” Also our CEO, Luigi Aurisicchio, talked about Takis’ story, discussing our team’s commitment and resilience, creating the innovative company we are today. Luciano Mocci, General Director of Federlazio - Associazione Piccole e Medie Imprese del Lazio and Board Director of Tecnopolo Roma, finally added how this area just outside Rome has become over time a leading hub for cutting-edge innovation and research. A heartfelt thanks to Rai News for this opportunity to share our work and vision with a wider audience! #tecnopolo #federlazio #research #innovation #pharma

Takis is thrilled to have participated with a poster in Europe’s largest event on #vaccine R&D! From the 28th to the 31st of October, the The World Vaccine Congress Europe 2024 gathered in Barcelona world-leading experts who explored the latest advances in vaccine technology, epidemic preparedness, therapies, zoonotic disease research, and more. With over 3,000 attendees, we had invaluable opportunities to network, gain insights from top innovators, and share our perspectives on the future of vaccine research. The Congress featured dynamic sessions like the Start-up Zone, Poster Zone, and new Working Groups, where group discussions allowed us to connect more with other professionals. We also presented a poster on the Development of Novel Genetic Vaccine Platforms: From the Idea to GMP Production, which we will share soon also here on LinkedIn. If you want to check it out, follow our LinkedIn page to stay updated!

Yesterday we had the pleasure to welcome to our facilities a delegation from Regione Lazio's Economic Development Council, led by the Ass. Roberta Angelilli, and by the BoD of the Tecnopolo Roma. During the visit, our guests had the opportunity to explore Takis’ state-of-the-art infrastructure, including our newly inaugurated BSL-3 lab, a key asset for advancing our #research. Visits like these play a vital role in enhancing #cooperation between the scientific community and #institutions. They create valuable moments for in-depth discussions on pivotal projects, groundbreaking innovations, and the challenges that drive our work forward. We extend our heartfelt gratitude to Roberta Angelilli and her team for their dedication and commitment to supporting our efforts. Collaborating with institutions is essential to accelerating scientific and technological advancements in the Lazio Region. We’re excited to build on this shared vision and continue contributing to the regional progress and innovation. #tecnopolo #regionelazio

Hear our CEO, Luigi Aurisicchio, speak about our newly inaugurated BSL-3 laboratory during Maker Faire Rome - The European Edition ! Our CEO discussed our work and #research, focusing in particular on our work to improve the #epidemicpreparedness. With our new BSL-3 laboratory, a state-of-the-art #facility, we can work on innovative research on a wide range of pathogens. The topic captured the attention of many participants and professionals attending the fair, providing an important opportunity to share knowledge and connect with people from various sectors. Check out Takis’ snapshot from the YouTube Maker Faire Rome page!

We had recently the honor of participating in the “Maker Faire Rome - The European Edition”, a major #event that celebrates innovation and creativity, bringing together businesses and enthusiasts from different sectors! Promoted by the Camera di Commercio Roma and organized by Innova Camera, Maker Faire Rome was a unique meeting point for companies, start-ups and students, bringing together a modern and visionary approach in doing business. On this occasion, our CEO, Luigi Aurisicchio, gave an inspiring #speech dedicated to our newly inaugurated BSL-3 laboratory. We are grateful to have participated at this important fair; we had the opportunity to bring our vision and mission to a wider audience, connecting with many companies from different sectors.

In the #MIRIA project, Takis is responsible for evaluating the #antiviral properties of nanocoatings by measuring the residual infectivity of #viral pathogens on eukaryotic cells after prolonged incubation with coated or uncoated materials at different temperature conditions. So far, Takis optimized an antiviral assay to check the properties of tested #nanocoatings against an engineered adenovirus able to be detected for measurement of viral activity. We recently had the chance to participate in the 5th Consortium Meeting of the MIRIA EU project, hosted in Grenoble by CEA, where we shared our latest results, contributing to the identification of the best nanocoatings candidates. MIRIA is an ambitious initiative focused on the development of antimicrobial, antiviral, and antifungal nanocoatings for everyday surfaces, with the goal of enhancing public #safety in environments where the risk of cross-contamination is high. We are excited to continue pushing the boundaries of science with our other EU partners, creating solutions that have the potential to significantly impact public #health across Europe!